The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

October 14, 2021

Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.

October 06, 2021

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

September 28, 2021

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

September 28, 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

September 24, 2021

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

September 19, 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

September 15, 2021

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

August 27, 2021

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

August 16, 2021

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

July 14, 2021

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

July 08, 2021

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

July 05, 2021

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

July 01, 2021

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

June 30, 2021

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

June 16, 2021

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

June 10, 2021

John C. Byrd, MD, discusses the rationale for the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

May 20, 2021

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

May 19, 2021

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

May 11, 2021

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.

May 10, 2021

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.